| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-18-1244 |
| P698 | PubMed publication ID | 31015311 |
| P50 | author | Razelle Kurzrock | Q56614941 |
| Benjamin Durham | Q37385072 | ||
| P2093 | author name string | Funda Meric-Bernstam | |
| Omar Abdel-Wahab | |||
| Filip Janku | |||
| Aaron M Goodman | |||
| Eli L Diamond | |||
| Shumei Kato | |||
| Tamara G Barnes | |||
| Vaijayanthi Kandadai Raghavan | |||
| P2860 | cites work | B-Raf mutation: a key player in molecular biology of cancer. | Q38155724 |
| Erdheim-Chester disease: characteristics and management | Q38210704 | ||
| BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System | Q38380202 | ||
| High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. | Q38692332 | ||
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. | Q38798543 | ||
| Histiocytoses: emerging neoplasia behind inflammation | Q39142018 | ||
| Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances | Q39334380 | ||
| Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders | Q40229747 | ||
| Novel MIR143-NOTCH fusions in benign and malignant glomus tumors | Q41867966 | ||
| Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease | Q42386218 | ||
| Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. | Q46031169 | ||
| Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing | Q47163678 | ||
| Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib | Q47297894 | ||
| First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study | Q49790677 | ||
| Single-agent dabrafenib for BRAFV600E-mutated histiocytosis. | Q52689208 | ||
| Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease. | Q54171656 | ||
| High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. | Q54491866 | ||
| Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer | Q57476349 | ||
| SOX2 amplification is a common event in squamous cell carcinomas of different organ sites | Q62029361 | ||
| Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies | Q88458406 | ||
| Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies | Q88461855 | ||
| Erdheim-Chester Disease: a comprehensive review of the literature | Q21202851 | ||
| ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression | Q24296658 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| MITF: master regulator of melanocyte development and melanoma oncogene | Q28256859 | ||
| Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha | Q28261747 | ||
| Guilty as charged: B-RAF is a human oncogene | Q28288202 | ||
| Response of histiocytoses to imatinib mesylate: fire to ashes | Q28291341 | ||
| Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases | Q28299567 | ||
| Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis | Q33416223 | ||
| Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. | Q33439784 | ||
| BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease | Q33976971 | ||
| PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers | Q33987852 | ||
| Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. | Q34239441 | ||
| Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease | Q34471821 | ||
| Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer | Q34501536 | ||
| Unique molecular landscapes in cancer: implications for individualized, curated drug combinations | Q34938532 | ||
| Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes | Q35636877 | ||
| Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA | Q35810461 | ||
| Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies | Q35828697 | ||
| Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood | Q36497457 | ||
| Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. | Q36553791 | ||
| A tale of two histiocytic disorders | Q36565617 | ||
| Actin capping protein CAPZB regulates cell morphology, differentiation, and neural crest migration in craniofacial morphogenesis†| Q36676795 | ||
| The distribution of BRAF gene fusions in solid tumors and response to targeted therapy | Q37308973 | ||
| Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages | Q37509422 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1149-1157 | |
| P577 | publication date | 2019-04-23 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis | |
| P478 | volume | 18 |
Search more.